Figure 5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Abigail Shea(Institute of Cancer Research), Alejandra Bruna(Institute of Cancer Research), Daniel Guerrero-Romero(University of Cambridge), Dimitra Georgopoulou(Age UK), Jean Abraham(Cancer Research UK), Louise Grybowicz(Cambridge University Hospitals NHS Foundation Trust), Martin O’Reilly(University of Cambridge), Jonny Lay(University of Cambridge), Sophia Wix(University of Cambridge), Agnese Giovannetti(Casa Sollievo della Sofferenza), Karen McAdam(Peterborough City Hospital), Elham Esmaeilishirazifard(Cancer Research UK Cambridge Center), Helen Bardwell(University of Cambridge), Raquel Manzano García(University of Cambridge), Yaniv Lubling(University of Cambridge), Giulia Lerda(Institute of Cancer Research), Maurizio Callari(Cancer Research UK), Alistair Martin(University of Cambridge), A. Nagano(The Francis Crick Institute), Riccardo Masina(University of Cambridge), Elena Provenzano(University of Cambridge), Steven Kupczak(Cancer Research UK Cambridge Center), Carlos Caldas(University of Cambridge), Justine Kane(University of Cambridge), Yi Cheng(University of Cambridge), Wei Cope(Cambridge University Hospitals NHS Foundation Trust), Oscar M. Rueda(University of Cambridge), Lisa Young(University of Cambridge), Wendy Greenwood(Howard Hughes Medical Institute)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Lung adenocarcinoma promotion by air pollutants
|Nature|2023|751